Next report date
Report period
Q1 2024
EPS estimate
−0.45USD
Revenue estimate
—
−8.5663USD
−124.12 MUSD
4.00 KUSD
32.31 M
About Biora Therapeutics, Inc.
Sector
Industry
CEO
Aditya P. Mohanty
Website
Headquarters
San Diego
Employees (FY)
58
Founded
2010
FIGI
BBG007K8X5S6
Biora Therapeutics, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. Its products include the Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer Test, and Resura Prenatal Test. The company was founded by Paul W. Hawran and Harry Stylli in 2010 and is headquartered in San Diego, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of BIOR is 0.6277 USD — it has increased by 3.41% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Biora Therapeutics, Inc. stocks are traded under the ticker BIOR.
Biora Therapeutics, Inc. is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
BIOR stock is 5.25% volatile and has beta coefficient of 0.32. Check out the list of the most volatile stocks — is Biora Therapeutics, Inc. there?
BIOR earnings for the last quarter are −4.89 USD per share, whereas the estimation was −0.93 USD resulting in a −428.65% surprise. The estimated earnings for the next quarter are −0.60 USD per share. See more details about Biora Therapeutics, Inc. earnings.
Yes, you can track Biora Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
BIOR stock has risen by 4.62% compared to the previous week, the month change is a 48.97% fall, over the last year Biora Therapeutics, Inc. has showed a 73.29% decrease.
BIOR net income for the last quarter is −15.41 M USD, while the quarter before that showed −73.45 M USD of net income which accounts for 79.02% change. Track more Biora Therapeutics, Inc. financial stats to get the full picture.
Today Biora Therapeutics, Inc. has the market capitalization of 22.52 M, it has decreased by 2.40% over the last week.
No, BIOR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BIOR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Biora Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 28, 2024, the company has 58.00 employees. See our rating of the largest employees — is Biora Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Biora Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Biora Therapeutics, Inc. stock shows the sell signal. See more of Biora Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Biora Therapeutics, Inc. future price: according to them, BIOR price has a max estimate of 15.00 USD and a min estimate of 5.60 USD. Read a more detailed Biora Therapeutics, Inc. forecast: see what analysts think of Biora Therapeutics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Biora Therapeutics, Inc. EBITDA is −66.59 M USD, and current EBITDA margin is −1.66 M%. See more stats in Biora Therapeutics, Inc. financial statements.